Finance

Lists
BIOCON:NSE
Biocon Ltd
₹ 350.60
-0.11%
(-0.40) 1D
10-р сарын 14, 15:30:00 (GMT+5:30)  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
₹ 353.00
High
₹ 353.00
Low
₹ 347.00
Mkt. cap
571.07Т
Avg. vol.
3.11 сая
Volume
3.38 сая
Dividend
0.14%
Quarterly dividend
₹ 0.13
Ex-dividend date
2026 оны 7-р сарын 3
P/E ratio
103.80
52-wk high
₹ 447.15
52-wk low
₹ 337.70
EPS
₹ 3.38
Shares outstanding
600.00 сая
No. of employees
16 мян
Open
₹ 353.00
High
₹ 353.00
Low
₹ 347.00
Mkt. cap
571.07Т
Avg. vol.
3.11 сая
Volume
3.38 сая
Dividend
0.14%
Quarterly dividend
₹ 0.13
Ex-dividend date
2026 оны 7-р сарын 3
P/E ratio
103.80
52-wk high
₹ 447.15
52-wk low
₹ 337.70
EPS
₹ 3.38
Shares outstanding
600.00 сая
No. of employees
16 мян
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16.4 мян
Founded1978 оны 11-р сарын 29
HeadquartersБангалор, Карнатака, Энэтхэг
Sector-
Websitebiocon.com
Last report
2026 оны 8-р сарын 6
Fiscal period
Q1 2027
₹ 0.95 / ₹ 1.09
-12.68%miss
Revenue / Est. (INR)
43.36 тэрбум / 44.74 тэрбум
-3.08%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
42.96 тэрбум
41.73 тэрбум
45.17 тэрбум
43.36 тэрбум
Cost of goods sold
17.72 тэрбум
13.39 тэрбум
23.69 тэрбум
14.68 тэрбум
Cost of revenue
17.72 тэрбум
13.39 тэрбум
23.69 тэрбум
14.68 тэрбум
Research and development expenses
-132.00 сая
-531.00 сая
-128.00 сая
-16.00 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.59 тэрбум
8.75 тэрбум
13.28 тэрбум
9.16 тэрбум
Operating expense
21.18 тэрбум
25.16 тэрбум
14.45 тэрбум
25.69 тэрбум
Total operating expenses
38.90 тэрбум
38.55 тэрбум
38.14 тэрбум
40.36 тэрбум
Operating income
4.05 тэрбум
3.18 тэрбум
7.03 тэрбум
3.00 тэрбум
Other non operating income
94.00 сая
1.17 тэрбум
-2.52 тэрбум
545.00 сая
EBT including unusual items
1.71 тэрбум
-678.00 сая
2.48 тэрбум
1.28 тэрбум
EBT excluding unusual items
1.23 тэрбум
2.26 тэрбум
1.80 тэрбум
1.41 тэрбум
Income tax expense
385.00 сая
-160.00 сая
489.00 сая
-92.00 сая
Effective tax rate
22.48%
23.60%
19.76%
-7.21%
Other operating expenses
6.72 тэрбум
11.78 тэрбум
-4.12 тэрбум
11.07 тэрбум
Net income
845.00 сая
1.44 тэрбум
1.26 тэрбум
1.41 тэрбум
Net profit margin
-
-
-
-
Earnings per share
0.72
2.74
1.27
0.95
Interest and investment income
235.00 сая
-
1.15 тэрбум
-
Interest expense
-2.72 тэрбум
-2.10 тэрбум
-2.06 тэрбум
-2.13 тэрбум
Net interest expenses
-2.49 тэрбум
-2.10 тэрбум
-906.00 сая
-2.13 тэрбум
Depreciation and amortization charges
4.73 тэрбум
5.15 тэрбум
5.13 тэрбум
5.47 тэрбум
EBITDA
8.69 тэрбум
7.13 тэрбум
11.62 тэрбум
7.59 тэрбум
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс